Americans contribute disproportionately toward the pharmaceutical innovation from which we all benefit, but their tolerance for subsidising the rest of the world is on the wane… Eric Crampton writes If philosophy students remember one thing from their lectures on Immanuel Kant in undergraduate classes, it is his categorical imperative. It’s easy to remember […]
Pharmac’s free ride won’t last forever
Pharmac’s free ride won’t last forever
04 Jul 2024 Leave a comment
in applied price theory, comparative institutional analysis, health economics Tags: drug lags
Recent Comments